Avoro Capital Advisors LLC is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $13.6 billion in regulatory assets under management. Its private funds, of all types, hold $13.6 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +21.5% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +81.9% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $13.6 billionForm ADV Item 5.F
- Gross assets of private funds
- $13.6 billionAll private fund types, Form ADV
- Hedge funds managed
- 12 private funds in total
- Employees
- 19Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 154091
- Latest Form ADV
- 03/05/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +18.8% | +14.8% |
| Q1 2026 | +2.3% | -4.6% |
| Q4 2025 | +22.2% | +2.4% |
| Q3 2025 | +33.1% | +7.8% |
| Q2 2025 | -0.9% | +10.4% |
| Q1 2025 | -7.2% | -4.5% |
| Q4 2024 | -2.5% | +2.1% |
| Q3 2024 | +2.6% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 30 share positions ($9,690,900,114) reported by Avoro Capital Advisors LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- United Therapeutics Corp Del15.41%
- Ascendis Pharma A/s11.87%
- Krystal Biotech Inc9.91%
- Argenx SE9.89%
- Madrigal Pharmaceuticals Inc9.53%
- Kymera Therapeutics Inc8.62%
- Arrowhead Pharmaceuticals In7.43%
- Revolution Medicines Inc4.54%
- Cytokinetics Inc3.33%
- Definium Therapeutics Inc2.77%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| United Therapeutics Corp Del | $1,493,207,699 | 15.41% | 2,755,555 | -0.80% |
| Ascendis Pharma A/s | $1,150,541,500 | 11.87% | 5,050,000 | -1.20% |
| Krystal Biotech Inc | $960,728,593 | 9.91% | 2,888,888 | Unchanged |
| Argenx SE | $958,910,000 | 9.89% | 1,000,000 | Unchanged |
| Madrigal Pharmaceuticals Inc | $923,926,499 | 9.53% | 1,833,333 | Unchanged |
| Kymera Therapeutics Inc | $835,601,967 | 8.62% | 7,474,747 | Unchanged |
| Arrowhead Pharmaceuticals In | $719,950,000 | 7.43% | 11,000,000 | -3.13% |
| Revolution Medicines Inc | $440,282,700 | 4.54% | 2,145,000 | -6.62% |
| Cytokinetics Inc | $322,959,000 | 3.33% | 4,900,000 | -2.00% |
| Definium Therapeutics Inc | $268,323,000 | 2.77% | 7,050,000 | -1.93% |
| Structure Therapeutics Inc | $204,992,205 | 2.12% | 6,555,555 | Unchanged |
| Xenon Pharmaceuticals Inc | $204,545,000 | 2.11% | 5,500,000 | -4.81% |
| Vera Therapeutics Inc | $181,954,150 | 1.88% | 5,635,000 | -1.55% |
| Uniqure NV | $162,543,092 | 1.68% | 6,727,777 | Unchanged |
| Celcuity Inc | $119,280,000 | 1.23% | 1,500,000 | -55.88% |
| Taysha Gene Therapies Inc | $116,338,885 | 1.20% | 23,888,888 | Unchanged |
| Ocular Therapeutix Inc | $94,956,901 | 0.98% | 12,380,300 | -1.27% |
| Damora Therapeutics Inc Com SHS | $80,502,240 | 0.83% | 3,783,000 | New |
| Hemab Therapeutics Hldgs Inc | $58,360,752 | 0.60% | 1,892,372 | -1.70% |
| Viridian Therapeutics Inc | $51,475,000 | 0.53% | 2,500,000 | Unchanged |
| Septerna Inc | $50,869,000 | 0.52% | 1,300,000 | -2.80% |
| Abivax SA | $48,321,760 | 0.50% | 488,000 | New |
| Scribe Therapeutics Inc | $47,834,098 | 0.49% | 2,598,973 | New |
| Faeth Therapeutics Inc | $41,933,400 | 0.43% | 1,410,000 | -2.36% |
| GH Research PLC | $41,559,600 | 0.43% | 1,770,000 | -1.67% |
| Biohaven Pharmaceutical Holding Co. LTD | $36,712,500 | 0.38% | 2,750,000 | New |
| Avalo Therapeutics Inc | $36,451,321 | 0.38% | 2,377,777 | +1.90% |
| Braveheart Bio Inc | $25,351,000 | 0.26% | 1,255,000 | New |
| Whitehawk Therapeutics Inc | $10,713,752 | 0.11% | 2,849,402 | Unchanged |
| Lexeo Therapeutics Inc | $1,774,500 | 0.02% | 525,000 | -64.75% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 5 new positions, 1 sold out, 1 increased, 15 reduced and 9 unchanged.
Number of positions (a count, not dollars)
- New positions5
- Increased1
- Unchanged9
- Reduced15
- Sold out1
New positions
| Stock | Value | Shares |
|---|---|---|
| Damora Therapeutics Inc Com SHS | $80,502,240 | 3,783,000 |
| Abivax SA | $48,321,760 | 488,000 |
| Scribe Therapeutics Inc | $47,834,098 | 2,598,973 |
| Biohaven Pharmaceutical Holding Co. LTD | $36,712,500 | 2,750,000 |
| Braveheart Bio Inc | $25,351,000 | 1,255,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Damora Therapeutics Inc | $98,395,830 | 3,783,000 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Avalo Therapeutics Inc | +44,444 | +1.90% | $36,451,321 | 2,377,777 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Celcuity Inc | -1,900,000 | -55.88% | $119,280,000 | 1,500,000 |
| Revolution Medicines Inc | -152,000 | -6.62% | $440,282,700 | 2,145,000 |
| Arrowhead Pharmaceuticals In | -355,555 | -3.13% | $719,950,000 | 11,000,000 |
| Ascendis Pharma A/s | -61,111 | -1.20% | $1,150,541,500 | 5,050,000 |
| United Therapeutics Corp Del | -22,222 | -0.80% | $1,493,207,699 | 2,755,555 |
| Xenon Pharmaceuticals Inc | -277,777 | -4.81% | $204,545,000 | 5,500,000 |
| Cytokinetics Inc | -99,999 | -2.00% | $322,959,000 | 4,900,000 |
| Definium Therapeutics Inc | -138,888 | -1.93% | $268,323,000 | 7,050,000 |
| Lexeo Therapeutics Inc | -964,189 | -64.75% | $1,774,500 | 525,000 |
| Vera Therapeutics Inc | -88,888 | -1.55% | $181,954,150 | 5,635,000 |
| Septerna Inc | -37,500 | -2.80% | $50,869,000 | 1,300,000 |
| Ocular Therapeutix Inc | -159,700 | -1.27% | $94,956,901 | 12,380,300 |
| Faeth Therapeutics Inc | -34,039 | -2.36% | $41,933,400 | 1,410,000 |
| Hemab Therapeutics Hldgs Inc | -32,778 | -1.70% | $58,360,752 | 1,892,372 |
| GH Research PLC | -30,000 | -1.67% | $41,559,600 | 1,770,000 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Celcuity Inc. | 13G amendment | 3.07% | 1,500,000 | Nov 16, 2026 | SEC.gov ↗ |
| Vera Therapeutics, Inc. | 13G amendment | 7.82% | 5,635,000 | Nov 16, 2026 | SEC.gov ↗ |
| Faeth Therapeutics, Inc. | 13G | 5.46% | 1,410,000 | Nov 16, 2026 | SEC.gov ↗ |
| Hemab Therapeutics Holdings, Inc. | 13G | 4.12% | 1,925,150 | Aug 14, 2026 | SEC.gov ↗ |
| Arrowhead Pharmaceuticals, Inc. | 13G amendment | 9.64% | 13,823,383 | Aug 14, 2026 | SEC.gov ↗ |
| Avalo Therapeutics, Inc. | 13G amendment | 4.44% | 2,333,333 | Aug 14, 2026 | SEC.gov ↗ |
| Scribe Therapeutics, Inc. | 13D | 13.78% | 2,598,973 | Jul 30, 2026 | SEC.gov ↗ |
| Centessa Pharmaceuticals plc | 13G amendment | 7.39% | 11,430,455 | May 15, 2026 | SEC.gov ↗ |
| Soleno Therapeutics Inc | 13G amendment | 4.45% | 2,300,000 | May 15, 2026 | SEC.gov ↗ |
| Xenon Pharmaceuticals, Inc. | 13G amendment | 6.26% | 5,777,777 | May 15, 2026 | SEC.gov ↗ |
| Damora Therapeutics, Inc. | 13G | 6.27% | 3,783,000 | May 15, 2026 | SEC.gov ↗ |
| Whitehawk Therapeutics, Inc. | 13D amendment | 19.99% | 15,893,516 | May 14, 2026 | SEC.gov ↗ |
| uniQure N.V. | 13G amendment | 9.87% | 6,150,000 | Feb 17, 2026 | SEC.gov ↗ |
| Avidity Biosciences, Inc. | 13G amendment | 5.54% | 8,515,792 | Feb 17, 2026 | SEC.gov ↗ |
| Definium Therapeutics, Inc. | 13G | 5.08% | 5,000,000 | Feb 17, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 14, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 19 companies. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (2)
As reported in the adviser's Form ADV filed Jun 4, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures